Skip to main content
. 2021 Apr 19;11(13):6507–6521. doi: 10.7150/thno.56367

Figure 3.

Figure 3

Ability of RGD-EVReN to target the lesion region of ischemic brain. (A) TTC-stained brain sections show the typical infarct area in a mouse receiving 1 h of MCAO and 24 h of reperfusion. (B) Representative NIRF images (overlaid with photograph) of mice brains which received MCAO/R and the administration of PBS, Cy5.5-labeled EVReN, Scr-EVReN or RGD-EVReN. Brains were dissected 24 h after administration (36 h after reperfusion). (C) Quantitation of fluorescence intensity (n = 5) in the lesion region. (D) Ratios of fluorescence intensity (n = 5) in ipsilateral versus contralateral region. Data in C and D are expressed as mean ± SEM. **P < 0.01 by One-way ANOVA. (E) Representative NIRF images of organs dissected from mice which received MCAO/R along with the administration of PBS, Cy5.5-labeled EVReN or RGD-EVReN. Organs were dissected 24 h after administration (36 h after reperfusion). Right boxed graph illustrates location of the analyzed six organs. (F) Quantitation of fluorescence intensities (n = 6) per gram of tissue in different organs. Data are expressed as mean ± SEM. *P < 0.05, ***P < 0.001 by One-way ANOVA.

HHS Vulnerability Disclosure